Transform Your Pharmacy’s Growth Potential with ACHC and Monarch Specialty Group. Click Here to learn more

January 2017



We support a broad collection of relevant news information for clients, as well as organizations evaluating our services.
Get market insights and strategies on orphan drugs and specialty drug pipeline, drug pricing, mergers and acquisitions, and up-to-date payor strategies relating to oncology, infectious disease (Hepatitis-C and HIV), multiple sclerosis, IVIG, and biosimilars, among others:

First DMD Drug Will Cost About $300,000, Be New Therapy for Specialty Pharmacies

“While initial infusions likely will occur in physician offices, it is “likely” that patients could transfer to home infusion administration, says Cichy. “Depending on Sarepta’s supply chain, it’s also possible that Exondys 51 could see utilization through physician clinics, hospital outpatient or ambulatory treatment centers…”